Abstract
Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
Highlights
Enfortumab vedotin (EV) is a novel treatment for patients with advanced urothelial carcinoma who have failed platinum-based chemotherapy and immunotherapy.[1]
Histopathology revealed subtle interface dermatitis accompanied by a perivascular lymphocytic infiltrate with eosinophils and neutrophils, marked dyskeratosis, and epidermal dysmaturation (Fig 2, A)
The rash improved with clobetasol ointment, 16 days after EV infusion, he was transferred to the medical intensive care unit for vasodilatory shock concerning hypersensitivity reaction and received prednisone
Summary
Cutaneous reactions with enfortumab vedotin: A case series and review of the literature. MD,a Cesar Antonio Virgen, MD, PhD,b Anna-Marie Hosking, MD,a Nataliya Mar, MD,c Linda Doan, MD, PhD,a Bonnie Lee, MD,a and Janellen Smith, MDa Irvine, California and Boston, Massachusetts
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
